<DOC>
	<DOCNO>NCT01564277</DOCNO>
	<brief_summary>This randomized phase II trial study well give rasburicase together allopurinol work treat patient hematologic malignancy . Rasburicase may reduce level uric acid blood . Allopurinol may stop growth cancer cell block enzymes need cell growth . It yet know dose rasburicase effective treat hematologic malignancy give together without allopurinol .</brief_summary>
	<brief_title>Rasburicase Allopurinol Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To prospectively evaluate efficacy , define uric acid response rate , 2 different single low dos rasburicase follow allopurinol 2 treatment arm . SECONDARY OBJECTIVES : I . To estimate proportion patient require additional dos rasburicase maintain uric acid level = &lt; 7.5mg/dL day 2 day 6 . II . To identify differential characteristic patient respond treatment . III . To measure area plasma uric acid concentration-time curve ( AUC ) baseline ( day 1 ) day 7 , time plasma uric acid level less equal 7.5mg/dL . IV . To evaluate rate patient require hemodialysis ( HD ) V. To evaluate safety low single-doses rasburicase . VI . To evaluate rate patient express double serum creatinine . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive 1.5mg rasburicase intravenously ( IV ) 30 minute day 1* allopurinol orally ( PO ) daily ( QD ) day 1-6 . ARM II : Patients receive 3 mg rasburicase IV 30 minute day 1* allopurinol PO QD day 1-6 . NOTE : *Patients serum uric acid &gt; = 7.5mg/dl also receive rasburicase IV day 2-3 . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) status 03 Active leukemia Burkitt leukemia/lymphoma treat inhouse put risk tumor lysis syndrome ( TLS ) Serum uric acid level &gt; = 7.5mg/dL high risk TLS define : A diagnosis acute myeloid leukemia ( AML ) , A diagnosis blastphase chronic myeloid leukemia ( CML ) , A diagnosis highgrade myelodysplastic syndrome ( MDS ) &gt; = 10 % blast bone marrow blast involvement , Acute lymphoblastic leukemia ( ALL ) , Burkitt leukemia/lymphoma Patient legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure History asthma History severe life threaten atopic allergy Hypersensitivity uricases Known prior sensitivity allopurinol Known glucose6phosphate dehydrogenase ( G6PD ) deficiency Recent prior history uricolytic therapy define therapy within last 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>